Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Melanoma, a malignant neoplasm, significantly contributes to global morbidity and mortality.
• Current immunotherapies primarily target tumor cells, with limited impact on the tumor microenvironment (TME).
• The TME, comprising non-tumor cells, extracellular matrix, and blood vessels, plays a crucial role in promoting melanoma malignancy, angiogenesis, and metastasis.

Purpose of the Study:

• To highlight novel therapeutic strategies targeting key cellular components within the melanoma TME.
• To investigate the roles of tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) in melanoma progression.
• To summarize the efficacy of therapies targeting TAMs and CAFs in preclinical and clinical settings.

Main Methods:

• Review of existing literature on melanoma, TME, TAMs, and CAFs.
• Analysis of preclinical and clinical trial data for targeted therapies.
• Discussion of the prognostic significance of TME constituents.

Main Results:

• TAMs and CAFs are identified as critical regulators of melanoma progression.
• Targeting TAMs and CAFs shows potential for improving therapeutic outcomes.
• The TME's heterogeneity influences both antitumor and pro-tumor effects.

Conclusions:

• Targeting TAMs and CAFs represents a promising therapeutic avenue for melanoma.
• Modulating the melanoma TME can enhance treatment efficacy and patient survival.
• Further research into TME-targeted therapies is warranted.